Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 7, 2020AntioxidantsOpen Access

Current Landscape of NRF2 Biomarkers in Clinical Trials

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYoko YagishitaFred Hutch Cancer CenterTGTonibelle Gatbonton-SchwagerCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South AfricaMMMelissa L. McCallumFred Hutch Cancer Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Yagishita et al. (2020) studied this question.

synapsesocial.com/papers/6a6f18d526770c2b8ddfd421https://doi.org/10.3390/antiox9080716
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fingolimod vs dimethyl fumarate in multiple sclerosis2018 · 47 citations
  2. 2Transcriptional changes in prostate of men on active surveillance after a 12-mo glucoraphanin-rich broccoli intervention—results from the Effect of Sulforaphane on prostate CAncer PrEvention (ESCAPE) randomized controlled trial2019 · 107 citations
  3. 3Sulforaphane Bioavailability and Chemopreventive Activity in Women Scheduled for Breast Biopsy2015 · 125 citations
  4. 4A Bibliometric Review of the Keap1/Nrf2 Pathway and its Related Antioxidant Compounds2019 · 98 citations
  5. 5Current Status of Metabolomic Biomarker Discovery: Impact of Study Design and Demographic Characteristics2020 · 100 citations